Fundamental Analysis of QUOIN PHARMACEUTICALS LT-ADR(NASDAQ:QNRX) stock

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to QNRX. QNRX was compared to 565 industry peers in the Biotechnology industry. QNRX may be in some trouble as it scores bad on both profitability and health. QNRX has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

QNRX had negative earnings in the past year.

In the past year QNRX has reported a negative cash flow from operations.

In the past 5 years QNRX always reported negative net income.

QNRX had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

QNRX's Return On Assets of -58.92% is in line compared to the rest of the industry. QNRX outperforms 41.35% of its industry peers.

QNRX has a Return On Equity of -110.74%. This is comparable to the rest of the industry: QNRX outperforms 42.96% of its industry peers.

		Industry Rank	Sector Rank
ROA	-58.92%
ROE	-110.74%
ROIC	N/A

ROA(3y)-122%

ROA(5y)-105.72%

ROE(3y)-1177.47%

ROE(5y)-750.96%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

QNRX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

QNRX has less shares outstanding than it did 1 year ago.

Compared to 5 years ago, QNRX has more shares outstanding

The debt/assets ratio for QNRX is higher compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of -6.11, we must say that QNRX is in the distress zone and has some risk of bankruptcy.

QNRX has a worse Altman-Z score (-6.11) than 65.95% of its industry peers.

A Debt/Equity ratio of 0.43 indicates that QNRX is not too dependend on debt financing.

QNRX has a worse Debt to Equity ratio (0.43) than 73.08% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.43
Debt/FCF	N/A
Altman-Z	-6.11

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 3.35 indicates that QNRX has no problem at all paying its short term obligations.

QNRX has a worse Current ratio (3.35) than 60.78% of its industry peers.

A Quick Ratio of 3.35 indicates that QNRX has no problem at all paying its short term obligations.

QNRX has a Quick ratio (3.35) which is comparable to the rest of the industry.

		Industry Rank	Sector Rank
Current Ratio	3.35
Quick Ratio	3.35

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

QNRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 69.04%, which is quite impressive.

EPS 1Y (TTM)69.04%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%75.9%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 25.87% on average over the next years. This is a very strong growth

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y77.65%

EPS Next 2Y37.08%

EPS Next 3Y25.87%

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

QNRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for QNRX. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

QNRX's earnings are expected to grow with 25.87% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y37.08%

EPS Next 3Y25.87%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for QNRX!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

QUOIN PHARMACEUTICALS LT-ADR

NASDAQ:QNRX (11/18/2024, 8:00:01 PM)

After market: 0.595 -0.01 (-0.83%)

0.6

-0.02 (-3.26%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap2.39M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-58.92%
ROE	-110.74%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0.43
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	3.35
Quick Ratio	3.35
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)69.04%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y77.65%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

QUOIN PHARMACEUTICALS LT-ADR (QNRX)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens